I. Pathological and clinical diversity in diffuse large B-cell lymphoma
- 17 June 2013
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 31 (S1) , 23-25
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaBlood, 2013
- Pathogenesis of Human B Cell LymphomasAnnual Review of Immunology, 2012
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingProceedings of the National Academy of Sciences, 2012
- Analysis of the coding genome of diffuse large B-cell lymphomaNature Genetics, 2011
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLBlood, 2010
- A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High AccuracyClinical Cancer Research, 2009
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- Cell cycle deregulation in B-cell lymphomasBlood, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002